Streptococcal B vaccine conjugate - Baxter International

Drug Profile

Streptococcal B vaccine conjugate - Baxter International

Latest Information Update: 12 Oct 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baxter International; Brigham and Womens Hospital; Harvard University
  • Class Conjugate-vaccines; Glycoconjugates; Polysaccharides; Streptococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Streptococcal infections

Most Recent Events

  • 16 Aug 2002 Preclinical trials in Streptococcal infections in USA (unspecified route)
  • 27 Jun 2000 North American Vaccine has been acquired by and merged into Baxter International
  • 30 Jun 1999 North American Vaccine has been awarded a US patent covering its unique Streptococcal B vaccine conjugate
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top